Common Contracts

Shares ADC THERAPEUTICS SA COMMON SHARES, NOMINAL VALUE CHF 0.08 PER SHARE UNDERWRITING AGREEMENT

Underwriting Agreement • September 21st, 2020 • ADC Therapeutics SA • Pharmaceutical preparations • New York

• Contract Type
  Underwriting Agreement
• Filed
  September 21st, 2020
• Company
  ADC Therapeutics SA
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Switzerland, and organized under the laws of Switzerland (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule II hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] common shares, nominal value CHF 0.08 per share (the “Firm Shares”), of the Company.

●] Shares ADC THERAPEUTICS SA COMMON SHARES, NOMINAL VALUE CHF 0.08 PER SHARE UNDERWRITING AGREEMENT

Underwriting Agreement • May 11th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations • New York

• Contract Type
  Underwriting Agreement
• Filed
  May 11th, 2020
• Company
  ADC Therapeutics SA
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This letter is being delivered to you in connection with the offering by ADC Therapeutics SA (the “Company”) of _____ common shares, nominal value CHF [●] per share (the “Common Shares”), of the Company and the lock-up letter dated ____, 2020 (the “Lock-up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated ____, 2020, with respect to ____ Common Shares (the “Shares”).

●] Shares ADC THERAPEUTICS SA COMMON SHARES, NOMINAL VALUE CHF 0.064 PER SHARE UNDERWRITING AGREEMENT

Underwriting Agreement • September 23rd, 2019 • ADC Therapeutics SA • Pharmaceutical preparations • New York

• Contract Type
  Underwriting Agreement
• Filed
  September 23rd, 2019
• Company
  ADC Therapeutics SA
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This letter is being delivered to you in connection with the offering by ADC Therapeutics SA (the “Company”) of _____ common shares, nominal value CHF [●] per share (the “Common Shares”), of the Company and the lock-up letter dated ____, 2019 (the “Lock-up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated ____, 2019, with respect to ____ Common Shares (the “Shares”).